Cyntellect Appoints Drs. Alan Aderem, Charles Cantor and Michael Hanley to Its Scientific Advisory Board

New members to foster expanded applications of cell-based manipulation from functional proteomics to stem cells

30-Jan-2007

Cyntellect, Inc. announced that it has appointed Drs. Alan Aderem, Charles Cantor and Michael Hanley to its Scientific Advisory Board (SAB). These three scientists along with the company's scientific founder, Dr. Bernhard Palsson, form an industry-seasoned Scientific Advisory Board to foster new, innovative and commercially-relevant applications of the company's laser-based live cell manipulation technology.

Dr. Alan Aderem is the Director of the Institute for Systems Biology which he co-founded with Drs. Leroy Hood and Rudy Aebersold. He is an immunologist and cell biologist and his current focus is the innate immune system. Prior to co-founding the ISB, Dr. Aderem was a faculty member at the University of Washington. Before that, he headed the Laboratory of Signal Transduction at The Rockefeller University. Dr. Aderem received his Ph.D. degree in biophysics and biology from the University of Cape Town in South Africa.

Dr. Charles Cantor is the Chief Scientific Officer of Sequenom and Chairman of its Scientific Advisory Board. In May 2000, Dr. Cantor was appointed to Sequenom's Board of Directors. Previously, he was the Chair and Professor of the Department of Biomedical Engineering, and Director of the Center for Advanced Biotechnology at Boston University. Dr. Cantor also held positions at Columbia University and the University of California, Berkeley. He was also the Director of the Human Genome Center Project of the Department of Energy at Lawrence Berkeley Laboratory.

Dr. Michael Hanley is currently Vice President, Discovery Research at Amylin Pharmaceuticals in San Diego, California. Prior to joining Amylin, Dr. Hanley held senior faculty positions at Imperial College, London, the Medical Research Council Laboratories, Cambridge, and the University of California at Davis. Dr. Hanley has served on advisory and review panels for the National Institutes of Health, the Medical Research Council and Wellcome Trust of Great Britain, and for the governments of Australia, Singapore, New Zealand, Hong Kong, Denmark and Japan. Prior to joining Amylin, Dr. Hanley was a senior consultant for healthcare investors in the venture capital and banking communities and for biotechnology companies such as Cell Therapeutics, Zymogenetics, Elan Pharmaceuticals, and Chiron Corporation. Dr. Hanley h received his B.S. in Biochemistry and his Ph.D. in Molecular Biology from the University of California, Berkeley.

https://www.bionity.com/en/news/61331/cyntellect-appoints-drs-alan-aderem-charles-cantor-and-michael-hanley-to-its-scientific-advisory-board.html